Outlook Therapeutics Inc (OTLK) volume hits 0.77 million: A New Opening for Investors

Outlook Therapeutics Inc (NASDAQ: OTLK) started the day on Wednesday, with a price decrease of -5.98% at $9.12, before settling in for the price of $9.70 at the close. Taking a more long-term approach, OTLK posted a 52-week range of $4.00-$40.60.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The Healthcare sector firm’s twelve-monthly sales growth has been 12.77% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 52.49%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 30.33%. This publicly-traded company’s shares outstanding now amounts to $13.01 million, simultaneously with a float of $7.40 million. The organization now has a market capitalization sitting at $118.65 million. At the time of writing, stock’s 50-day Moving Average stood at $8.34, while the 200-day Moving Average is $13.95.

Outlook Therapeutics Inc (OTLK) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Outlook Therapeutics Inc’s current insider ownership accounts for 43.15%, in contrast to 27.77% institutional ownership. According to the most recent insider trade that took place on Mar 28 ’24, this organization’s Director bought 1,882 shares at the rate of 11.82, making the entire transaction reach 22,242 in total value, affecting insider ownership by 5,049. Preceding that transaction, on Mar 07 ’24, Company’s CHIEF COMMERCIAL OFFICER bought 62,484 for 0.42, making the whole transaction’s value amount to 26,243. This particular insider is now the holder of 808,459 in total.

Outlook Therapeutics Inc (OTLK) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 12/30/2023, the organization reported -$0.8 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$1) by $0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.

Outlook Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 30.33% and is forecasted to reach -2.08 in the upcoming year.

Outlook Therapeutics Inc (NASDAQ: OTLK) Trading Performance Indicators

Let’s observe the current performance indicators for Outlook Therapeutics Inc (OTLK). It’s Quick Ratio in the last reported quarter now stands at 0.44. The Stock has managed to achieve an average true range (ATR) of 1.58.

In the same vein, OTLK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.99, a figure that is expected to reach -0.91 in the next quarter, and analysts are predicting that it will be -2.08 at the market close of one year from today.

Technical Analysis of Outlook Therapeutics Inc (OTLK)

If we take a close look at the recent performances of Outlook Therapeutics Inc (NASDAQ: OTLK), its last 5-days Average volume was 1.2 million that shows progress from its year to date volume of 0.58 million. During the previous 9 days, stock’s Stochastic %D was recorded 48.14% While, its Average True Range was 1.78.

Raw Stochastic average of Outlook Therapeutics Inc (OTLK) in the period of the previous 100 days is set at 52.24%, which indicates a major rise in contrast to 52.24% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 227.73% that was higher than 123.62% volatility it exhibited in the past 100-days period.